Background: Non Alcoholic Fatty Liver Disease (NAFLD) is becoming modern hepatic pandemic and NAFLD co-existing in patients with diabetics is supposed to have reduced beta cell function. Patients with NAFLD who have type 2 diabetes are particularly at risk of developing NASH and they are at higher risk of developing cirrhosis, also have poor glycemic control owing to reduced beta cell function. So identifying the patients with diabetes having NAFLD and β cell functional status could estimates the future risk and help in slowing the progression and prevention of chronic liver disease and various complications of Diabetes.

Material: This was a cross sectional observational study conducted in department of medicine, N.S.C.B., MCH, Jabalpur in which 100 cases of diabetes were taken who satisfied inclusion and exclusion criteria. Abdominal USG was used for evidence of fatty liver and it’s grading and fasting serum levels of insulin (FIL) and fasting blood sugar (FBS) were used to calculate HOMA-β value to get beta cell function.

Observation: HOMA-β values were calculated for all the patients of DM, which showed that lower mean HOMA-β values in patients with NAFLD and Diabetes i.e.37.56±24.03 as compared to 60.96±96.62 in Non NAFLD group of patients. β cell function was deranged in the patients with high BMI, Waist circumference. NAFLD group of patients have higher prevalence of diabetes related complications as compare to Non NAFLD group. Prevalence of NAFLD was slightly more in females-56.6%(n=30) as compared to males-55.32%(n=26).We found higher Mean BMI, Waist circumference, Triglycerides, FBS,FIL in cases with NAFLD (24.83±2.42, 95.11±12.46, 180.07±51.35, 176.13±66.79, 13.59±15.42) as compare to non NAFLD  (22.41±2.16, 85.84±9.86, 139.09±39.27, 134.8±34.41, 6.79±4.49) respectively. Lower HOMA-β values were significantly associated with raised BMI and WC.

Conclusion: As NAFLD is highly prevalent in diabetics, possibility of NAFLD should be considered in all of them. Patients with Diabetes who also have NAFLD, observed to have relatively reduced β cell function, However it is not significantly associated with Non NAFLD group probably because of already reduced β cell function reserve in diabetics However progressive decline in β cell function could estimate future risk of NASH and complications of diabetes. It seems reasonable to expect that early diagnosis of NAFLD and early intervention with strict glycemic control and weight loss would prevent complications.

1. Anjana RM, Pradeepa R, Deepa M, et al. ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India:phaseI results of the Indian Council of Medical Research-India Diabetes (ICMRINDIAB) study. Diabetologia 2011; 54:3022– 3027
2. Duseja A., Nonalcoholic fatty liver disease in India - a lot done, yet more required. Indian J Gastroenterol2010;29:217-25.
3. Singh SP, Nayak S, Swain M, et al. Prevalence of non alcoholic fatty liver disease in coastal eastern India: A preliminary ultrsonographic survey. Trop Gastroenterol2004;25:769
4. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitisin type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:854–858
5. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al, Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007 ;6:161-3.
6. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009; 84:84-91.
7. Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, Narayani, Juneja A. Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome. J Assoc Physicians India 2009;57:201-4.
8. Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009;57:205-10
9. International Diabetes Federation Diabetes Atlas.5.2012.Retrieved from http://www.idf.org/diabetesatlas/5e/southeast-asia.
10. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease. Practice Guideline by the American Association for the Study of Liver Disease, American College of Gastroenterology, and American Gastroenterology Association. Gastroenterology. 2012; 142:1592-1609
11. Wallace TM,  Levy JC, Matthews DR. Use and abuse of HOMA modeling, Diabetes Care, 2004, vol. 276(pg. 1487-1495)
12. Castro A, Scott JP, GrettkeDP : Plasma insulin and glucose response of healthy subjects to varying glucose loads during three-hour oral glucose tolerance test. Diabetes, 1970;19:842-851.
13. Reaven GM, Olefsky J, Farquhar JW : Does hyperglycemia or hypersumlinenimia characterize the patient with chemical diabetes? Lancet, 7763;1972:1247-11249.
14. Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001; 285:2486- 2497
15. McCullough AJ, Update on nonalcoholic fatty liver disease, J ClinGastroenterol, 2002;34:255– 62
16. S Merat1*, S Yarahmadi2, S Tahaghoghi1, Z Alizadeh3, N Sedighi3, N Mansournia1, A Ghorbani1, R Malekzadeh1; Prevalence of Fatty Liver Disease among Type 2 Diabetes Mellitus Patients and its Relation to Insulin Resistance; Middle East Journal of Digestive Diseases/ Vol.1/ No.2/ September 2009:74-79
17. Sanjay Kalra1, Manoj Vithalani2, Gurjeet Gulati3, CM Kulkarni4,Study of Prevalence of Nonalcoholic Fatty Liver Disease(NAFLD) in Type 2 Diabetes Patients in India (SPRINT); Journal of the association of physicians of india • july 2013 • VOL. 61;12-17
18. Bhatt KN, Pranav V, Dipika Y, Dharmesh N, Radhika N, Arvind S. Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus and its relation with insulin resistance in South Gujarat region. J Mahatma Gandhi Inst Med Sci 2017;22:8-11.
19. HajiehBibi Shahbazian1*, Seyed Jalal Hashemi 1, Seyed Mahmood Latifi 2, Gholamreza Lashkarara 1, Gholamreza, Alizadeh Attar Prevalence of Fatty Liver Disease and Its RiskFactors in Type 2 Diabetic Patients, Iranian Journal Of Diabetes And Obesity, Volume 3, Number 2, Summer 2011;83-87
20. Basaveshwar Mhetre et al / International Journal of Biomedical and Advance Research 2016; 7(2): 097-101.
21. Pratt DS, Kaplan MM,et al.Evaluation of abnormal liver enzymes results in asymptomatic patients. New England Journal of Medicine 2000;342:1266-1271.
22. Reid AE. Non alcoholic steatohepatitis. Gastroenterology 2001;121:710‑23
23. Sheth SG, Gordon FD, Chopra S. Non alcoholic steatohepatitis. Ann Intern Med 1997;126:137‑45
24. Salgado Júnior W, Santos JS, Sankarankutty AK, Silva Ode C. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras 2006;21Suppl 1:72‑8
25. Arun J, Clements RH, Lazenby AJ, Leeth RR, Abrams GA. The prevalence of nonalcoholicsteatohepatitis is greater in morbidly obese men compared to women. ObesSurg 2006;16:1351‑8.
26. Li FP, Zhang SQ, Wang F et al, Insulin resistance and islet beta cell function in type 2 diabetes mellitus and non alcoholic fatty liver disease, Zhonghua Nei Ke Za Zhi.2009 Nov;48(11):940-3.]
27. Sharavanan TKV et al., Sch. J. App. Med. Sci., August 2015; 3(5A):1834-1837
28. Nathalie C. Leite, Gil F. Salles, Antonio L. E. Araujo et al, Prevalence and associated factors of non-alcoholic fatty liver disease in patientswith type-2 diabetesmellitus; Liver International 2009:1478-3223;113-119
29. Fumiaki ImamuraKenneth J. Muka-mal  James B. Meigs José A. LuchsingerJ oachim H. Ix David S. Siscovick Dariush Mozaffarian, Risk Factors for Type 2 Diabetes Mellitus Preceded by β-Cell Dysfunction, Insulin Resistance, or Both in Older Adults: The Cardiovascular Health Study,American Journal of Epidemiology, Volume 177, Issue 12, 15 June 2013, Pages 1418–1429]

Dr Shivesh Thakur

Resident Medical, Officer, N.S.C.B.M.C.H. Jabalpur, M.P.

Address-16th Shivarth Residency, Jasuja City, Dhanvantari Nagar, Jabalpur, Pin-482003

Contact no.+917415209963, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.